drugset / Trial / NCT04054973
L-arginine Study for Persistent Symptoms of Schizophrenia
NaSingle-groupOpen-labelTreatment
Summary
The purpose of this research is to see if daily combination treatment of L-arginine and Kuvan changes brain chemistry in people experiencing schizophrenia as measured by MRS brain scans.
Timeline
- Start
- 2019-09-11
- Primary completion
- 2021-12-31
- Completion
- 2021-12-31
Outcome
Outcome not reported
Stopped: “Study was unable to be started due to unavailability of study medication.”
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | ARGININE | Small molecule | 6000 mg | — |
| Subject | sapropterin | Unknown | 800 mg | — |